Purchase this article with an account.
T. Buder, E. Lutjen–Drecoll; Effect of Latanoprost on ACAID in the Mouse Eye . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3788.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To assess the early and long term effect of latanoprost on anterior chamber associated immune deviation (ACAID) in mouse eyes. Methods: A single 150ng (3Âµl) dose of latanoprost was applied daily to the right eye of 36 Balb/c mice. After 4, 8, 12, 16, 20 and 24 weeks of treatment ACAID was performed in 6 mice of each group. A group of 12 untreated mice for each timespan (in total 72) served as a control for the ACAID experiments. Results: After four weeks of daily treatment the mice showed loss of ACAID. The same results were found after 8 and 12 weeks of latanoprost treatment. After 20 and 24 weeks the treated mice like the controls showed ACAID. After 16 weeks of treatment there were individual differences in the ACAID reaction between the animals. Conclusions: These data indicate that the early effect of latanoprost treatment in the mouse eye is comparable to that previously shown in primate eyes following short term treatment with PGF2alpha–isopropylesther. In addition the results reveal that under long term treatment ACAID is regained. Therefore the mice provide a suitable model for further studies of the mechanisms underlying the latanoprost effect on ACAID.
This PDF is available to Subscribers Only